U.S. Markets close in 5 hrs 7 mins

Competitor Recall Continues To Show Opportunities For ResMed

·1 min read
  • ResMed Inc (NYSE: RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million.

  • Adjusted EPS reached $1.49, up from $1.35 a year ago.

  • The company also increased its quarterly dividend to $0.44 from $0.42 per share.

  • Keybanc reiterates the Overweight rating and price target of $276.

  • The analyst says that after resetting near-term supply chain expectations, visibility appears to be increasing and management's tone seemed more optimistic around key moving pieces to Keybanc's thesis, including:

    • Q4 constant currency growth exceeded Keybanc's expectations, while FX limited more upside.

    • The management expects a sequential improvement in device production volumes through FY23 and an incremental step in masks & accessories growth.

    • Koninklijke Philips NV's (NYSE: PHG) recall issues continue to present opportunities for ResMed, and the company may finally be in a position to address more fully the opportunities presented by PHG's recall.

  • Price Action: RMD shares closed down 0.42% at $239.85 on Friday.

Latest Ratings for RMD

Date

Firm

Action

From

To

Jan 2022

Citigroup

Upgrades

Neutral

Buy

Jan 2022

RBC Capital

Upgrades

Underperform

Sector Perform

Jan 2022

JP Morgan

Upgrades

Neutral

Overweight

View More Analyst Ratings for RMD

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.